WHO Guide for standardisation of economic evaluations of immunization programmes

Vaccine

Volumn 28, Issue 11, 2010, Pages 2356-2359

  Walker, Damian G ^a   Hutubessy, Raymond ^b   Beutels, Philippe ^c  

^a Department of International Health   (United States)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c Centre for the Evaluation of Vaccination   (Belgium)

Author keywords

Cost effectiveness analysis; Economic evaluations; Guidelines; Immunization programmes; Vaccines

Indexed keywords

VACCINE;

ARTICLE; ECONOMIC ASPECT; HEALTH PROGRAM; HUMAN; IMMUNIZATION; PRIORITY JOURNAL; STANDARDIZATION; WORLD HEALTH ORGANIZATION;

COST-BENEFIT ANALYSIS; HUMANS; IMMUNIZATION PROGRAMS; WORLD HEALTH ORGANIZATION;

EID: 77249150382     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2009.06.035     Document Type: Article

References (32)

1. World Bank. World development report 1993: investing in health (1993), Oxford University Press, New York
2. Beutels P. Economic evaluations of hepatitis B immunization: a global review of recent studies (1994-2000). Health Econ 10 8 (2001) 751-774
3. Beutels P., and Postma M.J. Economic evaluations of adult pneumococcal vaccination: a review of the literature. Expert Rev Pharmacoecon Outcomes Res 1 1 (2001) 47-58
4. Beutels P. Potential conflicts of interest in vaccine economics research: a commentary with a case study of pneumococcal conjugate vaccination. Vaccine 22 25-26 (2004) 3312-3322
5. Beutels P., Thiry N., and VAN Damme P. Convincing or confusing? Economic evaluations of childhood pneumococcal conjugate vaccination-a review (2002-2006). Vaccine 25 8 (2007) 1355-1367
6. Brinsmead R., Hill S., and Walker D. Are economic evaluations of vaccines useful to decision-makers? Case study of Haemophilus influenzae type b vaccines. Pediatr Infect Dis J 23 1 (2004) 32-37
7. Edmunds W.J. Universal or selective immunisation against hepatitis B virus in the United Kingdom? A review of recent cost-effectiveness studies. Commun Dis Public Health 1 4 (1998) 221-228
8. Jefferson T., and Demicheli V. Is vaccination against hepatitis B efficient? A review of world literature. Health Econ 3 1 (1994) 25-37
9. Newall A.T., Beutels P., Wood J.G., Edmunds W.J., and MacIntyre C.R. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 7 4 (2007) 289-296
10. Pegurri E., Fox-Rushby J.A., and Damian W. The effects and costs of expanding the coverage of immunisation services in developing countries: a systematic literature review. Vaccine 23 13 (2005) 1624-1635
11. Thiry N., Beutels P., VAN Damme P., and Van Doorslaer E. Economic evaluations of varicella vaccination programmes: a review of the literature. Pharmacoeconomics 21 1 (2003) 13-38
12. Walker D., and Rheingans R. Cost-effectiveness of rotavirus vaccines. Expert Rev Pharmacoecon Outcomes Res 5 5 (2005) 593-601
13. Welte R., Trotter C.L., Edmunds W.J., Postma M.J., and Beutels P. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine. Pharmacoeconomics 23 9 (2005) 855-874
14. Kim S.Y., and Goldie S.J. Cost-effectiveness analyses of vaccination programmes: a focused review of modelling approaches. Pharmacoeconomics 26 3 (2008) 191-215
15. Beutels P., Scuffham P., and MacIntyre C.R. Funding of drugs: do vaccines warrant a different approach?. Lancet Infect Dis (2008)
16. Bilcke J., and Beutels P. Reviewing the cost effectiveness of rotavirus vaccination: the importance of uncertainty in the choice of data sources. Pharmacoeconomics 27 4 (2009) 281-297
17. Chiou C.F., Hay J.W., Wallace J.F., Bloom B.S., Neumann P.J., Sullivan S.D., et al. Development and validation of a grading system for the quality of cost-effectiveness studies. Med Care 41 1 (2003) 32-44
18. Brisson M., and Edmunds W.J. Impact of model, methodological, and parameter uncertainty in the economic analysis of vaccination programs. Med Decis Making 26 5 (2006) 434-446
19. World Health Organization. WHO Guide for standardization of economic evaluations of immunization programmes (2008), WHO, Geneva. http://www.who.int/immunization/documents/WHO_IVB_08.14/en/index.html WHO/IVB/08.04, http://www.who.int/immunization/documents/WHO_IVB_08.14/en/index.html
20. Tan Torres-Edejer T., Baltussen R., Adam T., Hutubessy R., Acharya A., Evans D.B., et al. Making choices in health: WHO guide to cost-effectiveness (2003), WHO, Geneva
21. Lee R.H. Future costs in cost effectiveness analysis. J Health Econ 27 4 (2008) 809-818
22. Weinstein M.C., Toy E.L., Sandberg E.A., Neumann P.J., Evans J.S., Kuntz K.M., et al. Modeling for health care and other policy decisions: uses, roles, and validity. Value Health 4 5 (2001) 348-361
23. Disease Control Priorities in developing countries. 2nd ed. New York: The World Bank; Oxford University Press; 2006.
24. Loewenstein G., and Prelec D. Anomalies in intertemporal choice: Evidence and an interpretation. Quart J Health Econ 107 2 (1992) 573
25. Harvey C. Proportional discounting of future costs and benefits. Math Oper Res 20 2 (1995) 381-399
26. World Health Organization Commission on Macroeconomics and Health. Macroeconomics and health: investing in health for economic development. Report of the Commission on Macroeconomics and Health. Geneva: World Health Organization; 2001.
27. Beutels P., Van Doorslaer E., VAN Damme P., and Hall J. Methodological issues and new developments in the economic evaluation of vaccines. Expert Rev Vaccines 2 5 (2003) 649-660
28. Welte R., van den D.G., Bos J.M., de Melker H., van Alphen L., Spanjaard L., et al. Economic evaluation of meningococcal serogroup C conjugate vaccination programmes in The Netherlands and its impact on decision-making. Vaccine 23 4 (2004) 470-479
29. Bos J.M., Rumke H., Welte R., and Postma M.J. Epidemiologic impact and cost-effectiveness of universal infant vaccination with a 7-valent conjugated pneumococcal vaccine in the Netherlands. Clin Ther 25 10 (2003) 2614-2630
30. Andrus J.K., Toscano C.M., Lewis M., Oliveira L., Ropero A.M., Davila M., et al. A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO's ProVac initiative. Public Health Rep 122 6 (2007) 811-816
31. Musgrove P. Public spending on health care: how are different criteria related?. Health Policy 47 3 (1999) 207-223
32. The GAVI Alliance's new vaccine strategy. Lancet 2008;372(9632):2.